# UCB SA (UCBJY)

> Source: Nexqual · https://nexqual.com/UCBJY · data as of 2026-10-23 17:11 UTC · cite as "Nexqual, UCB SA (UCBJY), nexqual.com/UCBJY" · informational, not investment advice.

**Price:** USD 152.12 (+5.13% today) · US market open, as of October 23, 2026 at 17:11 UTC; quotes may be delayed. Prev close 144.7 · day 147.59–152.2 · 52w 110.55–168.76 · market cap $57.9B · PNK

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 173.42 (range 161.93–184.92).
- Total return with dividends: 1Y +6.7% vs S&P 500 +14.4%; 5Y +167.5% vs S&P 500 +77.0%.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 173.42 (low 161.93, high 184.92).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +6.7% | +167.5% |
| S&P 500 (SPY) | +14.4% | +77.0% |
| Per year | +6.7% | +21.8% |
| Volatility (annualized) | 40.9% | 34.1% |
| Max drawdown | -33.7% (Feb 2026→Oct 2026) | -45.9% (Apr 2022→Sep 2022) |

## Peers (Biotechnology)
ARGX (argenx SE) USD 878.59 +0.32% · ONC (BeOne Medicines Ltd.) USD 376.65 -1.47% · MRNA (Moderna, Inc.) USD 204.16 +0.75% · RVMD (Revolution Medicines, Inc.) USD 188.9 +0.64% · REGN (Regeneron Pharmaceuticals, Inc.) USD 807.01 -1.47% · RPRX (Royalty Pharma plc) USD 63.81 +0.09%

## More
Full page: https://nexqual.com/UCBJY · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2026-12-31) | $6.32 | $5.52 | +14.3% | $8.77B | 2 |
| Next fiscal year (ends 2027-12-31) | $7.08 | $6.73 | +5.1% | $9.72B | 2 |